Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)

Barinthus Biotherapeutics' Convertible Debt history spans 1 years, with the latest figure at $44.7 million for Q4 2020.

  • For Q4 2020, Convertible Debt changed N/A year-over-year to $44.7 million; the TTM value through Dec 2020 reached $44.7 million, changed N/A, while the annual FY2020 figure was $44.7 million, N/A changed from the prior year.
  • Convertible Debt reached $44.7 million in Q4 2020 per BRNS's latest filing.
  • In the past five years, Convertible Debt ranged from a high of $44.7 million in Q4 2020 to a low of $44.7 million in Q4 2020.